Related Experiment Videos
Temozolomide: a novel oral alkylating agent
1Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK.
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
Temozolomide offers an oral alternative to dacarbazine (DTIC) for cancer treatment, effectively crossing the blood-brain barrier. Its good tolerability supports combination therapy, with ongoing research into new uses and resistance strategies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Temozolomide is an oral imidazotetrazine chemotherapy agent.
- It shares similarities in mechanism and efficacy with dacarbazine (DTIC).
Purpose of the Study:
- To review the properties and clinical applications of temozolomide.
- To highlight its advantages over dacarbazine and its potential in combination chemotherapy.
Main Methods:
- Review of existing clinical trials and pharmacological data for temozolomide.
- Analysis of temozolomide's pharmacokinetic and pharmacodynamic properties.
Main Results:
- Temozolomide is orally bioavailable, spontaneously degrades to an active metabolite, and penetrates the blood-brain barrier.
- It is well tolerated, showing efficacy in advanced metastatic melanoma and high-grade malignant glioma.
Conclusions:
- Temozolomide is a promising agent for treating brain tumors and melanoma, suitable for combination regimens.
- Further investigations are exploring new indications and methods to overcome drug resistance for enhanced efficacy.